Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications

被引:5
|
作者
Tamma, Seetha M. [1 ]
Hsu, Alice J. [2 ]
Tamma, Pranita D. [3 ]
机构
[1] Long Isl Univ, Dept Biomed Sci, New York, NY USA
[2] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, 200 North Wolfe St,Suite 3149, Baltimore, MD 21287 USA
关键词
CEPHALOSPORIN CXA-101 FR264205; INFECTIOUS-DISEASES SOCIETY; URINARY-TRACT-INFECTIONS; IN-VIVO ACTIVITIES; PSEUDOMONAS-AERUGINOSA; PIPERACILLIN-TAZOBACTAM; DOUBLE-BLIND; ANTIMICROBIAL ACTIVITY; PLUS METRONIDAZOLE; BETA-LACTAMASES;
D O I
10.1007/s40272-015-0157-x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Antibiotics are arguably the greatest medical development of the 20th century but these precious resources are being threatened by the continued rise in infections caused by multidrug-resistant bacteria. There is concern that we are on the precipice of a 'post-antibiotic era'. The situation is exacerbated by a stagnation in the pharmaceutical industry in developing new antibiotics, particularly those with activity against some of the most resistant Gram-negative organisms because of significant economic, scientific, and regulatory barriers. One of the products of recent initiatives to reinvigorate the antibiotic pipeline is the agent ceftolozane/tazobactam. Ceftolozane/tazobactam was approved in December 2014 by the US Food and Drug Administration for the treatment of complicated urinary tract infections and complicated intra-abdominal infections for patients 18 years of age and older. The safety and effectiveness of ceftolozane/tazobactam in pediatric patients has not been established in clinical studies. However, with the rise of highly drug-resistant Gram-negative organisms in children and the current climate of ongoing, multiple, and simultaneous antibiotic shortages-particularly of broad-spectrum antibiotics, the potential off-label role of ceftolozane/tazobactam for children needs to be explored while pediatric studies are ongoing. The objective of this opinion piece is to discuss what is currently known about ceftolozane/tazobactam and its potential implications for use in the pediatric population.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications
    Seetha M. Tamma
    Alice J. Hsu
    Pranita D. Tamma
    Pediatric Drugs, 2016, 18 : 1 - 11
  • [2] Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis
    Arrieta, Antonio C.
    Ang, Jocelyn Y.
    Zhang, Zufei
    Larson, Kajal B.
    Yu, Brian
    Johnson, Matthew G.
    Rhee, Elizabeth G.
    Feng, Ed H.
    Rizk, Matthew L.
    PEDIATRIC PULMONOLOGY, 2020, 55 (08) : 2025 - 2032
  • [3] Ceftolozane/Tazobactam Dose Selection for Pediatric Patients (birth to < 18 years)
    Larson, Kajal B.
    Patel, Yogesh T.
    Willavize, Susan
    Rizk, Matthew L.
    Yu, Brian
    Johnson, Matthew G.
    Rhee, Elizabeth G.
    Caro, Luzelena
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S87 - S87
  • [4] CEFTOLOZANE-TAZOBACTAM DOSING IN PATIENTS WITH CYSTIC FIBROSIS
    Rusnak, A.
    Sakon, C.
    Wrin, J.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S248 - S248
  • [5] A real-world investigation into prescribing patterns and effectiveness of ceftolozane/tazobactam among critically ill patients from SPECTRA
    Soriano, Alex
    Paterson, David L.
    Thalhalmmer, Florian
    Kluge, Stefan
    Viale, Pierluigi
    Akrich, Brune
    Allen, Mike
    Wirbel, Stephanie
    Watanabe, Alexandre H.
    Yuecel, Emre
    Obi, Engels N.
    Kaul, Sundeep
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2025, 111 (04)
  • [6] EXTENDED-SPECTRUM GRAM-NEGATIVE ANTIBIOTIC PRESCRIBING AROUND A CEFTOLOZANE/TAZOBACTAM SHORTAGE
    Self, Jenna
    Wilson, Nicole
    Spence, Matthew
    Nguyen, Jeffrey
    Grauer, Dennis
    CRITICAL CARE MEDICINE, 2024, 52
  • [7] Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
    Criscuolo, Marianna
    Trecarichi, Enrico Maria
    ANTIBIOTICS-BASEL, 2020, 9 (02):
  • [8] Pediatric anesthesia: current status and future directions
    Kuratani, Norifumi
    Kanmura, Yuichi
    JOURNAL OF ANESTHESIA, 2016, 30 (02) : 185 - 186
  • [9] Pediatric anesthesia: current status and future directions
    Norifumi Kuratani
    Yuichi Kanmura
    Journal of Anesthesia, 2016, 30 : 185 - 186
  • [10] Pharmacokinetics of ceftolozane/tazobactam continuous infusion on renal replacement therapy: A pediatric case report
    Collignon, Charlotte
    Gana, Ines
    Benaboud, Sihem
    Toubiana, Julie
    Castelle, Martin
    Oualha, Mehdi
    de Marcellus, Charles
    THERAPIE, 2022, 77 (05): : 616 - 620